OSOn behalf of the OG Prehabilitation Group and AUGIS (Association of Upper GI Surgeons)
On behalf of the OG Prehabilitation Group and AUGIS (Association of Upper GI Surgeons)
+6
Introduction: Studies have demonstrated that prehabilitation in oesophagogastric cancer (OGC) improves body composition, physical fitness and quality of life, and can reduce surgical complications. However, it is not offered in all OGC centres. Furthermore, definitions, funding and access to services vary. We conducted a survey of prehabilitation in OGC centres in England and Wales. Methods: OGC centres were identified through the National Oesophago-Gastric Cancer Audit (NOGCA). Survey questions were developed, piloted in two institutions and distributed via email in October 2022. Reminder emails were sent over two months until the survey closed in December 2022. Results: Responses were received from 28 of 36 centres. There was near-universal agreement that prehabilitation should be considered standard of care for patients on curative pathways (27/28; 96%). Most centres (21/28; 75%) offered prehabilitation. The majority of respondents believed that prehabilitation should commence at diagnosis (27/28; 96%) and consist of at least aerobic training and dietitian input. Most (26/28; 93%) believed access to clinical psychologists should be included; however, only 12 (43%) had access to clinical psychologists. Respondents believed prehabilitation improves quality of life (26/28; 93%), fitness (26/28; 93%), smoking cessation (28/28; 100%), surgical complication rates (25/28; 89.3%), likelihood of proceeding to surgery (25/28; 89.3%) and overall survival (20/28; 71.4%). Conclusions: Despite barriers to funding and a lack of best practice guidelines, most units deliver prehabilitation. Units require higher quality evidence, consensus on the most important aspects of the intervention and core outcome sets to support the delivery of services and facilitate audit to assess the impact of their introduction.
Background: Prehabilitation is increasingly being used in patients undergoing multimodality treatment for oesophagogastric cancer (OGC). Most studies to date have been small, single-centre trials. This collaborative study sought to assess the overall impact of prehabilitation on patient outcomes following OGC surgery. Methods: Data came from four prospective prehabilitation trials conducted in the UK or Ireland in patients undergoing multimodality treatment for OGC. The studies included three randomised and one non-randomised clinical trial, each comparing a prehabilitation intervention group to controls. The prehabilitation interventions included aerobic training delivered by exercise physiologists alongside dietetic input throughout the treatment pathway. The primary outcome was survival (all-cause and disease-specific mortality). Secondary outcomes were differences in complications, cardio-respiratory fitness (changes in VO2 peak and anaerobic threshold (AT)), chemotherapy completion rates, hospital length of stay, changes in body mass index, tumour regression and complication rates of anastomotic leak and pneumonia. Cox and logistic regression analysis provided hazard ratios (HR) and odds ratios (OR), respectively, with 95% confidence intervals (CI), adjusted for confounders. Results: Among 165 patients included, 88 patients were in the prehabilitation group and 77 patients were in the control group. All-cause and disease-specific mortality were not improved by prehabilitation (HR 0.67 95% CI 0.21–2.12 and HR 0.82 95% CI 0.42–1.57, respectively). The prehabilitation group experienced fewer major complications (20% vs. 36%, p = 0.034; adjusted OR of 0.54; 95%CI 0.26–1.13). There was a mitigated decline in VO2 peak following neo-adjuvant therapy (delta prehabilitation −1.07 mL/kg/min vs. control −2.74 mL/kg/min; p = 0.035) and chemotherapy completion rates were significantly higher following prehabilitation (90% vs. 73%; p = 0.016). Hospital length of stay (10 vs. 12 days, p = 0.402) and neoadjuvant chemotherapy response (Mandard 1–3 41% vs. 35%; p = 0.494) favoured prehabilitation, albeit not statistically significantly. Conclusion: Despite some limitations in terms of heterogeneity of study methodology, this study suggests a number of meaningful clinical benefits from prehabilitation before surgery for OGC patients. Current initiatives to agree on national standards for delivering prehabilitation and the results of ongoing trials will help to further refine this important intervention and expand the evidence base to support the widespread adoption and implementation of prehabilitation programs.
Background Symptoms after upper gastrointestinal (UGI) cancer surgery are common, frequently overlap, and can substantially affect quality of life. Despite increasing recognition of this problem, there is limited standardisation in the definition, investigation and management of the postoperative conditions responsible for these symptoms. Methods A society-endorsed, European-wide series of consensus meetings was conducted using a modified Delphi process developed by the PeriOperative Quality Initiative (POQI). A multidisciplinary panel of experts from 10 European countries, selected for their expertise in UGI cancer survivorship, participated in the development of consensus-based recommendations for symptoms following major UGI cancer surgery. Independent oversight was provided by POQI, and statements and recommendations were graded using a modified GRADE methodology informed by a comprehensive literature review. Results A total of 8 statements and 13 recommendations relating to symptom monitoring and service provision after major UGI cancer surgery were developed, refined and agreed upon through a preliminary meeting and two semistructured POQI consensus meetings. Diagnostic criteria, investigation pathways and management recommendations for the common postoperative conditions encountered after UGI cancer surgery were also developed and refined through multidisciplinary discussion before achieving consensus. 16 future research priorities were identified. Conclusions The EUROSTAR consensus provides guidance on symptom monitoring, service provision and the investigation and management of common postoperative conditions following UGI cancer surgery. These recommendations represent an important step towards standardising survivorship care and supporting future research in this patient population.
Introduction: Circulating donor‐derived cell‐free DNA (dd‐cfDNA) has emerged as a noninvasive biomarker for detecting allograft rejection and assessing renal status. While promising, its diagnostic test accuracy (DTA) remains unclear. This study aimed to evaluate the DTA of dd‐cfDNA in identifying rejection following renal transplantation. Method: A systematic review and meta‐analysis of DTA studies were conducted following PRISMA guidelines. Electronic databases (MEDLINE via PubMed, Embase, Scopus and Web of Science) were searched comprehensively for studies reporting the sensitivity and specificity of dd‐cfDNA in detecting renal allograft rejection. Data were analysed using Review Manager (RevMan) 5.4.1 and MetaDTA 2.0. Results: Thirteen studies were included, comprising 2214 samples across various rejection types, including antibody‐mediated rejection (ABMR) and T cell–mediated rejection (TCMR). Meta‐analysis revealed pooled sensitivities and specificities for detecting unspecified rejection of 61.1% (95% CI: 48.2%–74.8%) and 83.0% (95% CI: 76.3%–88.5%), respectively. For ABMR, pooled sensitivity increased to 75.6% (95% CI: 61.7%–86.4%) with a specificity of 82.1% (95% CI: 71.4%–88.8%). Meta‐regression analysis using a dd‐cfDNA threshold of 1% demonstrated comparable sensitivity and specificity for the detection of biopsy‐proven rejection and ABMR, yielding estimates consistent with the overall pooled results. Insufficient data were available to allow for analytical comparison in TCMR. The area under the curve (AUC) was highest in the ABMR group. Conclusion: dd‐cfDNA shows potential as a diagnostic biomarker, particularly for ABMR in renal transplantation. Further studies integrating dd‐cfDNA with biochemical and histological markers are recommended to enhance diagnostic precision.